News | News By Subject | News by Disease News By Date | Search News

Anxiety News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Marinus Pharma (MRNS)'s Primary Endpoint Not Met in Ganaxolone Phase II     6/28/2016
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Teva Pharmaceutical Industries Limited (TEVA) Wins Approval for First Generic Lexapro for Depression; Awarded 180-Day Period of Marketing Exclusivity     3/15/2012
Pfizer Inc. (PFE)'s (JOBS) Lyrica Receives Complete Response Letter From FDA For Generalized Anxiety Disorder Monotherapy Treatment; Data in the NDA Insufficient to Support Approval     12/28/2009
FDA Approves Eli Lilly and Company (LLY)'s (JOBS) Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder     11/30/2009
Sepracor, Inc. (SEPR) Drug Lunesta Fails in Anxiety Trial     3/6/2009
Eli Lilly and Company (LLY) (JOBS), Boehringer Ingelheim Corporation Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder     8/22/2008
European CHMP Issues Positive Opinion on Eli Lilly and Company (LLY)'s Cymbalta for the Treatment of Generalised Anxiety Disorder     6/27/2008
AstraZeneca PLC (AZN) Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines     5/8/2008
FDA Approves Jazz Pharmaceuticals, Inc. (JAZZ)'s Luvox(R) CR Extended-Release Capsules for the Treatment of Social Anxiety Disorder and Obsessive Compulsive Disorder     2/29/2008
Jazz Pharmaceuticals, Inc. (JAZZ) Says FDA Accepts Additional Data on Luvox     2/1/2008
FDA Issues Approvable Letter for Jazz Pharmaceuticals, Inc. (JAZZ)'s LUVOX(R) CR Extended-Release Capsules for the Treatment of Social Anxiety Disorder and Obsessive Compulsive Disorder     12/26/2007
FDA Approves Eli Lilly and Company (LLY)'s Cymbalta(R) for Treatment of Generalized Anxiety Disorder     2/26/2007

News from Around the Web
Bionomics Limited (BNO.AX): A Company With Deals On The Horizon     7/5/2017
Traveling To Mars Might Cause Long-Term Brain Damage     10/12/2016
Psychopaths Feel Fear But See No Danger, Vrije Universiteit Amsterdam Study     8/31/2016
New Brain Tweak Can Help You Combat Your Fear Of Spiders, Uppsala Universitet Study     8/26/2016
Prenatal BPA Exposure Linked To Anxiety And Depression In Boys, Columbia University Study     8/17/2016
Dog Fear And Aggression Genes Related To Human Anxiety, Nationwide Children's Hospital     8/12/2016
Women Twice As Likely As Men To Experience Anxiety, University of Cambridge Research Reveals     6/6/2016
Popular Pain Med Lyrica Linked To Major Birth Defects, Lausanne University Hospital Study     5/19/2016
Parkinson's Meds Up Risk Of Compulsive Gambling, Shopping, Binge Eating, Loyola University Health System Study     4/6/2016
Brain Boost: Office Of Naval Research Global Sponsors Research To Improve Memory Through Electricity     3/2/2016
Mom And Dad Make Up 45% Of Medical Marijuana Patients, HelloMD Reveals     2/24/2016
Parents' Anxiety, Depression Linked To Kids Being Fussy Eaters, Erasmus MC Study     2/23/2016
Popular Anxiety Meds May Not Lead To Dementia After All, University of Washington Study     2/8/2016
Chronic Stress And Anxiety Can Damage The Brain, Baycrest Health Sciences Study     1/22/2016
Anxiety Significantly Raises Risk For Dementia, University of Southern California Study     12/21/2015

Press Releases
FAU Research Provides Clues To Treat Depression, Autism And Other Neuropsychiatric Disorders     9/22/2017
Tonix Pharma (TNXP) Receives European Patent For The Active Ingredient In Tonmya (Cyclobenzaprine HCL Sublingual Tablets)     9/15/2017
Tonix Pharma (TNXP) Presented Additional Phase II Clinical Results In Military-Related PTSD And Design Of Ongoing Phase III Trial At The 2017 Military Health System Research Symposium     8/30/2017
Tonix Pharma (TNXP) To Present Additional Phase II Clinical Results And Design Of Ongoing Phase III Trial In Military-Related PTSD At The 2017 Military Health System Research Symposium     8/21/2017
Amneal Issues Voluntary Nationwide Recall Of Lorazepam Oral Concentrate, USP 2mg/mL     8/15/2017
Tonix Pharma (TNXP) Announces Conditional Acceptance Of Tonmya As Proposed Brand Name For TNX-102 SL (Cyclobenzaprine HCL Sublingual Tablets) For The Treatment Of PTSD     7/6/2017
Medibio Release: Scientific Breakthrough On Objective Diagnosis Of PTSD     6/26/2017
Tonix Pharma (TNXP) Participated In The "Pathophysiology Of Posttraumatic Stress Disorder: Rethinking Drug Targets” Summit Sponsored By U.S. Department Of Defense     6/15/2017
Tonix Pharma (TNXP) To Present An Update Of FDA Designated Breakthrough Therapy-TNX-102 SL For PTSD At The 2017 Marcum Microcap Conference     6/12/2017
Tonix Pharma (TNXP) Presented Retrospective Analyses Of Treatment Response And Remission To TNX-102 SL In A Phase II Military-Related PTSD Study     5/31/2017
Tonix Pharma (TNXP) To Present Additional Clinical Results Of Military-Related PTSD Study At The 2017 American Society Of Clinical Psychopharmacology Annual Meeting     5/24/2017
Tonix Pharma (TNXP) Release: Company Presented Details Of Newly Expanded Product Development Pipeline At 9th Annual Biotech Showcase Conference     1/11/2017
Tonix Pharma (TNXP) Presented New Clinical Results From Sub-Group Analysis Of Phase II Atease Study In Military-Related Posttraumatic Stress Disorder (PTSD)     12/8/2016
NYU Langone Medical Center Release: Single Dose Of Hallucinogenic Drug Psilocybin Relieves Anxiety And Depression In Patients With Advanced Cancer     12/1/2016
DolCas Biotech Release: BCM-95 Targets Anxiety And Depression; Positive Results For Natural Dosing Of Curcumin For Depression     11/23/2016

//-->